Lit­tle Capri­cor hits the brakes on a stem cell tri­al for Duchenne MD fol­low­ing an al­ler­gic re­ac­tion

The pen­ny stock play­er Capri­cor Ther­a­peu­tics $CAPR has stum­bled in­to an­oth­er pit­fall. 

The biotech not­ed that it has vol­un­tar­i­ly halt­ed a clin­i­cal tri­al of a stem cell ther­a­py they had hoped would tamp down on the dam­ag­ing in­flam­ma­tion as­so­ci­at­ed with Duchenne mus­cu­lar dy­s­tro­phy. The halt was called fol­low­ing a “se­vere al­ler­gic re­ac­tion” that oc­curred dur­ing in­fu­sion, ac­cord­ing to a fil­ing with the SEC.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER